登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：600521 证券简称：华海药业 公告编号：临2025-120号 债券代码：110076 债券简称：华海转债 浙江华海药业股份有限公司 关于股东部分股份解除质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担个别及连带责任。 重要内容提示: ● 截至本公告披露日，浙江华海药业股份有限公司（以下简称"公司"）5%以上股东周明华先生持有公 司股份总数为224,418,890股，占公司总股本的比例为14.99%。本次股份解除质押后，周明华先生处于 质押状态的股份累计数为57,500,000股，占其所持有公司股份总数的25.62%，占公司总股本的比例为 3.84%。 特此公告。 浙江华海药业股份有限公司 ■ 本次解除质押后，周明华先生所持公司股份后续如有质押计划，公司将依据相关规定及时履行信息披露 义务。 二、股份质押情况 截至本公告披露日，周明华先生累计质押股份情况如下： 单位：股 ■ 一、本次股份解除质押情况 近日，公司接到股东周明华先生的通知，其质押给上海浦东发展银行股份有 ...

关于股东部分股份解除质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 | 证券代码：600521 | 证券简称：华海药业 | 公告编号：临 | 2025-120 号 | | --- | --- | --- | --- | | 债券代码：110076 | 债券简称：华海转债 | | | 浙江华海药业股份有限公司 二、股份质押情况 截至本公告披露日，周明华先生累计质押股份情况如下： 重要内容提示: 截至本公告披露日，浙江华海药业股份有限公司（以下简称"公司"） 5%以上股东周明华先生持有公司股份总数为 224,418,890 股，占公司总股本的比 例为 14.99%。本次股份解除质押后，周明华先生处于质押状态的股份累计数为 57,500,000 股，占其所持有公司股份总数的 25.62%，占公司总股本的比例为 3.84%。 一、本次股份解除质押情况 近日，公司接到股东周明华先生的通知，其质押给上海浦东发展银行股份有 限公司张江科技支行的公司股份 648 万股已办理了解除质押手续，具体情况如 下: 单位：股 | 股东 ...

11月24日，华海药业大宗交易成交100万股，成交额1652万元，占当日总成交额的5.47%，成交价16.52 元，较市场收盘价17.03元折价2.99%。 | 股重重要提逾 | | | | | | --- | --- | --- | --- | --- | | 交易日期 | 证券商标 | 证券代码 | 成交价(元) 成交金额(万元) 成交量( *) 买入营业部 | 卖出营业部 是否为专场 | | 2025-11-24 | 华海药业 | 600521 | 机构专用 16.52 1652 100 | Ka 星座早期間了解發 | ...

Core Viewpoint - The domestic R&D demand is showing marginal improvement, driven by the overseas expansion of innovative drugs, leading to a recovery in R&D orders and stabilization of industry prices after a decline in 2023. The CRO sector is expected to see better performance growth by 2026, while the CDMO industry has also reached a bottom and is poised for continued strong growth due to robust demand for new molecules and new orders [1][2][3]. CRO Sector - The domestic R&D demand is recovering, with an increase in orders and stabilization of prices, indicating a clear upward trend for CRO companies. Clinical CROs like Tigermed, Nossan, and Prasis are expected to see revenue growth turning positive by 2025, with significant contributions from overseas business [2][3]. - The recognition of domestic CRO clinical data is improving, which is beneficial for companies like Tigermed [2]. CDMO Sector - The CDMO sector has seen a recovery in performance, with new orders continuing to improve quarterly. The global demand for innovative drug R&D is driving growth in new orders and backlog [3]. - The industry is benefiting from increased capacity utilization and profitability, with a strong certainty of performance and profit growth expected to continue into 2026 [3]. Life Sciences Sector - The life sciences upstream sector is experiencing a dual drive from domestic substitution and overseas expansion, with urgent demand for domestic alternatives in areas like cell culture media and biological reagents. Companies are expected to capture market share through new product categories and cost-effective offerings [4]. - The demand for specific segments such as drug efficacy, antibodies, and proteins is increasing, indicating a clear long-term growth logic for the industry [4]. API Sector - The raw material pharmaceutical industry is currently in a phase of price bottoming and supply surplus, with traditional product performance under pressure. However, companies are extending their business into generics, innovative drugs, and specialty APIs, which may lead to value reconstruction through business structure optimization [5]. - The valuation of raw material pharmaceutical companies is at a low point, presenting opportunities based on changes in new business layouts [5]. Investment Recommendations - For clinical and preclinical CROs, companies like Tigermed, Nossan, and Yinos are recommended due to the gradual recovery of the industry and expected improvement in order structure [6]. - In the CDMO sector, companies such as WuXi AppTec, WuXi Biologics, and others with strong fundamentals and capacity advantages are highlighted for their potential benefits from industry recovery and high demand for new molecules [6]. - In the life sciences upstream sector, companies like Baitai Biotechnology and others are recommended due to accelerated domestic substitution and strong overseas growth [6]. - Companies like Pro Pharma and Huahai Pharmaceutical are noted for their new business layouts that are expected to contribute significant value increments [6].

登录新浪财经APP 搜索【信披】查看更多考评等级 股票简称：华海药业 股票代码：600521 公告编号：临2025-119号债券简称：华海转债 债券代码： 110076 浙江华海药业股份有限公司 评价HB0017注射液治疗中重度斑块状银屑病的疗效和安全性的多中心、随机、双盲、安慰剂对照的III 期临床研究已顺利完成揭盲，总计共纳入408例中国中重度斑块状银屑病患者。研究结果显示，研究达 到预设的所有主要疗效终点（第12周时达到PASI 75（PASI评分较基线改善≥75%）的受试者比例、第12 周时达到sPGA 0/1（sPGA评分为0分或1分）的受试者比例）和关键次要疗效终点（第12周达到PASI 90 （PASI较基线改善≥90%）的受试者比例）。维持治疗期给药方案有望实现同类产品给药间隔最长，且 各种疗效指标在维持治疗期持续升高并保持稳定。相较于同靶点已上市产品，HB0017的核心治疗期 （前12周）和维持治疗期（12-52周）疗效数据均展现有力的竞争优势。安全性方面，HB0017整体安全 性和耐受性良好，与前期临床研究数据及同靶点药物相比，常见的不良事件类型和严重程度均在预期范 围，未发现新的安全性风 ...

证券日报网讯 11月19日晚间，华海药业发布公告称，近日，公司下属子公司上海华奥泰生物药业股份 有限公司（简称"华奥泰"）、华博生物医药技术（上海）有限公司（系华奥泰全资子公司）自主研发的 HB0017注射液用于治疗银屑病的多中心、双盲、随机、安慰剂平行对照的关键性临床试验达到主要疗 效终点和所有关键次要疗效终点。 （文章来源：证券日报） ...

关于子公司药物临床试验进展的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 | 股票简称：华海药业 | 股票代码：600521 | 公告编号：临 | 号 2025-119 | | --- | --- | --- | --- | | 债券简称：华海转债 | 债券代码：110076 | | | 浙江华海药业股份有限公司 银屑病是一种慢性、复发性、免疫介导的炎症性皮肤病，累及全身皮肤及其他 器官系统。我国银屑病的患病率为 0.5%左右，可发生于各年龄段，大约 80%至 90%的银屑病病例为斑块状银屑病。银屑病患者不但患上多种并发症的几率增高， 常合并其他系统性疾病，如心血管疾病、代谢性疾病、肝肾疾病、自身免疫性疾病 等，比如银屑病关节炎、心力衰竭、肥胖症、高血压、糖尿病和代谢综合征等；同 时患者也承受着巨大的精神痛苦，抑郁、焦虑以及身体和精神痛苦双重压力导致的 自杀倾向等精神疾病在银屑病患者中较为常见。因此银屑病是一种严重影响患者身 心健康的疾病，是一个世界性急需解决的疾患。 HB0017 注射液是华奥泰自主研发的以白介 ...

Core Viewpoint - Huahai Pharmaceutical's HB0017 injection has successfully met primary and key secondary efficacy endpoints in a pivotal clinical trial for the treatment of psoriasis [1][2] Group 1: Clinical Trial Results - The Phase III clinical study for HB0017 injection included 408 patients with moderate to severe plaque psoriasis and achieved all predefined primary efficacy endpoints, including PASI75 and sPGA0/1 at week 12 [2] - The treatment regimen during the maintenance phase is expected to offer the longest dosing interval among similar products, with efficacy indicators continuing to rise and remain stable during this period [2] - HB0017 demonstrated strong competitive advantages in both the core treatment phase (first 12 weeks) and the maintenance phase (weeks 12-52) compared to already marketed products targeting the same pathway [2] Group 2: Safety and Tolerability - HB0017 exhibited good overall safety and tolerability, with adverse event types and severity aligning with expectations based on prior clinical studies and similar drugs, with no new safety risk signals identified [2] Group 3: Product Development and Future Prospects - HB0017 is a monoclonal antibody targeting interleukin-17A (IL-17A) and is intended for treating moderate to severe plaque psoriasis, ankylosing spondylitis, and other autoimmune diseases [3] - In addition to the completed Phase III trial for plaque psoriasis, the company is concurrently conducting a Phase III trial for ankylosing spondylitis, with promising efficacy and safety results from previous Phase II studies [3] - The company has invested approximately RMB 372 million in the development of the HB0017 injection project to date [3]

Core Viewpoint - Huahai Pharmaceutical's HB0017 injection has successfully met primary and key secondary efficacy endpoints in a pivotal clinical trial for the treatment of psoriasis [1][2] Group 1: Clinical Trial Results - The Phase III clinical study for HB0017 injection included 408 patients with moderate to severe plaque psoriasis and achieved all predefined primary efficacy endpoints, including PASI75 and sPGA0/1 at week 12 [2] - The treatment regimen during the maintenance phase is expected to offer the longest dosing interval among similar products, with efficacy indicators continuing to rise and remain stable during this period [2] - HB0017 demonstrated strong competitive advantages in both the core treatment phase (first 12 weeks) and the maintenance phase (weeks 12-52) compared to already marketed products targeting the same pathway [2] Group 2: Safety and Tolerability - The overall safety and tolerability of HB0017 are good, with adverse event types and severity aligning with expectations based on previous clinical studies and similar drugs, with no new safety risk signals identified [2] Group 3: Product Development and Future Plans - HB0017 is a monoclonal antibody targeting interleukin-17A (IL-17A) and is intended for treating moderate to severe plaque psoriasis, ankylosing spondylitis, and other autoimmune diseases [3] - In addition to the completed Phase III trial for plaque psoriasis, the company is concurrently conducting a Phase III trial for ankylosing spondylitis, with promising efficacy and safety data from a Phase II trial [3] - The company has invested approximately RMB 372 million in the development of the HB0017 injection project to date [3]

Group 1: Financing and Investment Plans - Shengyi Electronics plans to raise no more than 2.6 billion yuan through a private placement to invest in AI computing HDI production base, smart manufacturing high-layer circuit board projects, and to supplement working capital and repay bank loans [2] - Lianmicro intends to invest 2.262 billion yuan to construct a project with an annual production capacity of 1.8 million pieces of 12-inch heavily doped substrate wafers [3] - Daimei Co. plans to invest 100 million yuan to establish a wholly-owned subsidiary focused on robotics technology [5] Group 2: Stock Performance and Trading - Furi Shares experienced a significant stock price fluctuation, with an 8-day cumulative deviation of 113.94%, indicating potential irrational speculation [2] - Tianfu Communication has set the initial inquiry transfer price at 140 yuan per share, reflecting a 7.2% discount from the closing price [7] - Ningde Times' third-largest shareholder is transferring shares at a price of 376.12 yuan per share, with full subscription from 16 institutional investors [6] Group 3: Operational Updates - Yongtai Technology's wholly-owned subsidiary is set to begin trial production of a lithium battery additive project with an annual capacity of 5,000 tons, increasing the total capacity to 10,000 tons per year [3] - Trina Solar's subsidiary signed contracts for the sale of 2.66 GWh of energy storage products, which is expected to positively impact future operating performance [5] - Yinglian Co. signed a strategic procurement contract for over 50 million square meters of composite aluminum foil materials for quasi-solid-state batteries, which will enhance its operational development in 2026-2027 [5] Group 4: Corporate Restructuring and Management - Huaxia Happiness has been designated a temporary manager for pre-restructuring by the court, pending a decision on its restructuring application [8] - The National Integrated Circuit Fund has reduced its stake in Shengke Communication by 2.49%, completing its planned share reduction [4]